The results of treatment of patients with urolithiasis by Renotinex® in early postoperative period


DOI: 10.29188/2222-8543-2020-13-4-35-40

S.V. Kotov, A.A. Nemenov, I.D. Boeva
№4 2020

Introduction. The article analyzes the results of the clinical application of the herbal complex Renotinex®, which helps to normalize the function of the urinary tract, reduce pain, remove small stones from the kidneys and reduce the risk of recurrent stone formation.

Materials and methods. At the University Clinic of Urology, Russian National Research Medical University named after N.I. Pirogov, a prospective, single-center, randomized study was carried out from November 2019 to March 2020. All patients underwent contact ureterolithotripsy. The patients were divided evenly into 2 groups: group A (n = 30) – patients receiving Renotinex® from the first day after surgery (within 1 month), and group B (n = 30) – a control group of patients not receiving specific therapy.

Results. After 1 month of continuous use of the drug, there was an increase in the percentage of calculi discharge after contact ureterolithotripsy, a decrease in the severity of pain, normalization of the temperature curve and the absence of subfebrile condition in all patients.

Conclusion. Renotinex® has a lithokinetic effect, its active ingredients contribute to the prevention of infectious and inflammatory complications of urolithiasis.

Read in the source